---
layout: default
title: Alpha -Tocopherol Beta -Carotene American Ginseng 
parent: 僅模型預測 (L5)
nav_order: 251
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Beta -Carotene American Ginseng 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Immune Support Combination: Insufficient Data for TxGNN Repurposing Evaluation

## One-Sentence Summary

This candidate is a complex multi-ingredient combination comprising antioxidants (α-tocopherol, β-carotene, ascorbic acid, selenium), herbal extracts (American ginseng, echinacea, *Phytolacca americana* root), micronutrients (pyridoxine, zinc), and porcine glandular extracts (adrenal gland, spleen, thymus), with a profile consistent with an immune-modulating nutritional supplement.
The TxGNN pipeline did not generate any repurposing predictions for this combination — likely due to the absence of a resolvable DrugBank ID for the multi-ingredient entry.
As a result, **no evidence-based new indication can be assessed at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None documented (no approved indications on record) |
| Predicted New Indication | None (TxGNN prediction not generated) |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no model output available |
| US Market Status | Not marketed (Taiwan: 未上市; 0 approved licenses) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this entry; therefore, a mechanistic rationale analysis is not applicable.

Based on ingredient composition, the combination presents a profile broadly consistent with immune support and antioxidant therapy:

- **Antioxidant components** (α-tocopherol, β-carotene, ascorbic acid, selenium) are commonly co-formulated to address oxidative stress in chronic and infectious disease contexts.
- **Herbal immune modulators** (American ginseng, echinacea) have been studied in the context of upper respiratory tract infections and general immune enhancement, though evidence for formal indications remains inconsistent.
- **Porcine glandular extracts** (thymus, spleen, adrenal gland) have historical use in glandular therapy, with the thymic fractions (thymosin-like peptides) investigated for immunodeficiency states, though regulatory acceptance is limited.
- **Phytolacca americana root** (pokeweed) contains mitogenic lectins (pokeweed mitogen) with in vitro B- and T-cell stimulatory effects, but its toxicity profile raises significant safety concerns at therapeutic doses.

Before any repurposing pathway can be opened, the combination must first be disaggregated: individual active components should be matched to their respective DrugBank IDs so that the TxGNN pipeline can be run per ingredient, and results subsequently consolidated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination as a unified entity.

---

## Literature Evidence

Currently no related literature available for this combination under a unified drug identifier. Individual ingredients (e.g., ascorbic acid, zinc, echinacea) have extensive separate literatures that fall outside the scope of this unified repurposing evaluation.

---

## US Market Information

No approved licenses found. This combination is not registered in the queried regulatory databases.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Additional note**: *Phytolacca americana* root (pokeweed root) is associated with significant gastrointestinal, haematological, and neurological toxicity. Even at low doses in combination products, this ingredient warrants explicit toxicological review before any clinical development pathway is considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline was unable to generate predictions because the multi-ingredient INN string could not be mapped to a single DrugBank ID, leaving the model without a valid input node in the knowledge graph. Without a prediction score or evidence base, no repurposing direction can be evaluated or recommended.

**To proceed, the following is needed:**

- **DrugBank ID resolution**: Decompose the combination into individual components and retrieve individual DrugBank IDs (e.g., DB00163 for vitamin E, DB00126 for vitamin C, DB00165 for pyridoxine).
- **Per-ingredient TxGNN run**: Re-run the pipeline for each resolvable component separately, then aggregate predictions across the combination.
- **Formulation intent clarification**: Determine whether this is a proprietary fixed-dose combination product or a compounded preparation, and identify its intended therapeutic area (e.g., immunodeficiency, oncology supportive care, general wellness).
- **Phytolacca safety review**: Commission a dedicated toxicological assessment for pokeweed root before any clinical consideration.
- **Original indication documentation**: Retrieve package insert or prescribing history from the originating market to establish a baseline indication for comparison.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

